82538-0
CALR gene exon 9 full mutation analysis in Blood or Tissue by Molecular genetics method
Active
Term Description
Full sequencing analysis of exon 9 in the CALR gene is performed to establish a diagnosis of essential thrombocythemia (ET) or primary myelofibrosis (PMF).[OMIM: 109091] All the pathologic CALR mutations reported to date are frame-shift mutations due to somatic insertions or deletions. PMID: 24325359 Two variants, a 52-base pair deletion (c.1092_1143del, L367fs*46) and a 5-bp insertion (c.1154_1155insTTGCC, K385fs*47), are the more common and account for more than 80% of the CALR mutations seen. PMID: 24325356 Variants outside of exon 9 are not detected by this test.
Part Descriptions
LP189734-9 CALR gene exon 9
The CALR (calreticulin) gene [HGNC Gene ID: 1455] is located on chromosome 19p13.3-p13.2. Calreticulin is a multifunctional protein that acts as a major Ca(2+)-binding (storage) protein in the lumen of the endoplasmic reticulum. It is also found in the nucleus, suggesting that it may have a role in transcription regulation. Calreticulin binds to the synthetic peptide KLGFFKR, which is almost identical to an amino acid sequence in the DNA-binding domain of the superfamily of nuclear receptors. Calreticulin binds to antibodies in certain sera of systemic lupus and Sjogren patients which contain anti-Ro/SSA antibodies, it is highly conserved among species, and it is located in the endoplasmic and sarcoplasmic reticulum where it may bind calcium. The amino terminus of calreticulin interacts with the DNA-binding domain of the glucocorticoid receptor and prevents the receptor from binding to its specific glucocorticoid response element. Calreticulin can inhibit the binding of androgen receptor to its hormone-responsive DNA element and can inhibit androgen receptor and retinoic acid receptor transcriptional activities in vivo, as well as retinoic acid-induced neuronal differentiation. Thus, calreticulin can act as an important modulator of the regulation of gene transcription by nuclear hormone receptors. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen but this was later disproven. Increased autoantibody titer against human calreticulin is found in infants with complete congenital heart block of both the IgG and IgM classes. [provided by RefSeq, Jul 2008][HGNC Gene ID:811]
Source: National Center for Biotechnology Information (NCBI) Gene
LP189734-9 CALR gene exon 9
Somatic mutations located in exon 9 of the CLAR gene are found in a about 65-85% of patients with myeloproliferative neoplasms, including essential thrombocythemia (ET) and primary myelofibrosis (PMF), and with nonmutated JAK2 and MPL genes. PMID: 24325359 The clinical course for patients with CLAR mutations are associated with longer risk of thrombosis and longer overall survival compared to patients with JAK2 mutations. PMID: 24325356 Over 160 unique mutations have been found in the CALR gene.[COSMIC: CALR]
Source: Regenstrief LOINC
Fully-Specified Name
- Component
- CALR gene exon 9 full mutation analysis
- Property
- Find
- Time
- Pt
- System
- Bld/Tiss
- Scale
- Doc
- Method
- Molgen
Additional Names
- Long Common Name
- CALR gene exon 9 full mutation analysis in Blood or Tissue by Molecular genetics method
- Short Name
- CALR Exon 9 Full Mut Anl Bld/T
- Display Name
- CALR gene exon 9 full mutation analysis Molgen Doc (Bld/Tiss)
- Consumer Name Alpha Get Info
- CALR gene Exon 9 variant analysis, Blood or tissue specimen
Associated Observations
81247-9 Master HL7 genetic variant reporting panel
| LOINC | Name | R/O/C | Cardinality | Example UCUM Units |
|---|---|---|---|---|
| 81247-9 | Master HL7 genetic variant reporting panel | |||
| Indent81306-3 | Variables that apply to the overall study | |||
| Indent Indent53577-3 | Reason for study | O | 0..* | |
| Indent Indent51967-8 | Genetic disease assessed [ID] | O | 0..* | |
| Indent Indent51963-7 | Medication assessed [ID] | C | 0..* | |
| Indent Indent48018-6 | Gene studied [ID] | C | 0..* | |
| Indent Indent36908-2 | Gene mutations tested for in Blood or Tissue by Molecular genetics method Nominal | C | 0..* | |
| Indent Indent51959-5 | Range(s) of DNA sequence examined | C | 0..* | |
| Indent Indent81293-3 | Description of ranges of DNA sequences examined | C | 0..1 | |
| Indent Indent51968-6 | Discrete variation analysis overall interpretation | R | 1..1 | |
| Indent Indent83006-7 | Deletion-duplication overall interpretation | C | ||
| Indent Indent51969-4 | Genetic analysis report | O | 0..1 | |
| Indent Indent81291-7 | Variant ISCN | C | ||
| Indent Indent62374-4 | Human reference sequence assembly version | C | 0..1 | |
| Indent Indent81303-0 | HGVS version [ID] | O | 0..1 | |
| Indent Indent82115-7 | dbSNP version [ID] | O | 0..1 | |
| Indent Indent83007-5 | COSMIC version [ID] | O | ||
| Indent Indent83008-3 | ClinVar version [ID] | O | ||
| Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent83005-9 | Variant category | |||
| Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent81297-4 | Structural variant panel | |||
| Indent Indent82155-3 | Genomic structural variant copy number | {#} | ||
| Indent Indent81299-0 | Structural variant reported arrCGH [Ratio] | C | 0..1 | {Ratio} |
| Indent Indent81300-6 | Structural variant [Length] | O | 0..1 | {#} |
| Indent Indent81301-4 | Structural variant outer start and end | O | 0..1 | {Range} |
| Indent Indent81302-2 | Structural variant inner start and end | O | 0..1 | {Range} |
| Indent81251-1 | Complex genetic variant panel | 0..n | ||
| Indent Indent81260-2 | Complex genetic variant [ID] | C | 0..1 | |
| Indent Indent81262-8 | Complex variant HGVS name | C | 0..1 | |
| Indent Indent81263-6 | Complex variant type | C | 0..1 | |
| Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent53034-5 | Allelic state | O | 0..1 | |
| Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent Indent83005-9 | Variant category | |||
| Indent Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent Indent82309-6 | Basis for allelic phase [Type] | O | ||
| Indent82118-1 | Pharmacogenomics result panel | |||
| Indent Indent48018-6 | Gene studied [ID] | 1..* | ||
| Indent Indent84413-4 | Genotype display name | |||
| Indent Indent53040-2 | Genetic variation's effect on drug metabolism | C | 0..1 | |
| Indent Indent51961-1 | Genetic variation's effect on drug efficacy | C | 0..1 | |
| Indent Indent83009-1 | Genetic variation's effect on high-risk allele | |||
| Indent Indent82117-3 | Medication usage implications panel | O | 0..* | |
| Indent Indent Indent51963-7 | Medication assessed [ID] | R | 1..* | |
| Indent Indent Indent82116-5 | Medication usage suggestion [Type] | C | 1..1 | |
| Indent Indent Indent83010-9 | Medication usage suggestion [Narrative] | C | ||
| Indent83011-7 | Haplotype definition panel | |||
| Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent81250-3 | Discrete genetic variant panel | 0..n | ||
| Indent Indent Indent83005-9 | Variant category | |||
| Indent Indent Indent81252-9 | Discrete genetic variant | C | 0..1 | |
| Indent Indent Indent48018-6 | Gene studied [ID] | C | 0..1 | |
| Indent Indent Indent51958-7 | Transcript reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent48004-6 | DNA change (c.HGVS) | C | 0..1 | |
| Indent Indent Indent48005-3 | Amino acid change (pHGVS) | C | 0..1 | |
| Indent Indent Indent48019-4 | DNA change type | O | 0..1 | |
| Indent Indent Indent48006-1 | Amino acid change [Type] | O | 0..1 | |
| Indent Indent Indent48013-7 | Genomic reference sequence [ID] | C | 0..1 | |
| Indent Indent Indent81290-9 | Genomic DNA change (gHGVS) | C | ||
| Indent Indent Indent69547-8 | Genomic ref allele [ID] | C | 0..1 | |
| Indent Indent Indent81254-5 | Genomic allele start-end | C | 0..1 | |
| Indent Indent Indent69551-0 | Genomic alt allele [ID] | C | 0..1 | |
| Indent Indent Indent84414-2 | Haplotype name | O | ||
| Indent Indent Indent81255-2 | dbSNP [ID] | O | 0..1 | |
| Indent Indent Indent81257-8 | CIGAR [ID] | O | 0..1 | |
| Indent Indent Indent48001-2 | Cytogenetic (chromosome) location | O | 0..1 | |
| Indent Indent Indent48002-0 | Genomic source class [Type] | O | 0..1 | |
| Indent Indent Indent81304-8 | Variant analysis method [Type] | O | ||
| Indent Indent Indent53037-8 | Genetic variation clinical significance [Imp] | O | 0..1 | |
| Indent Indent Indent69548-6 | Genetic variant assessment | O | ||
| Indent Indent Indent81259-4 | Associated phenotype | O | 0..1 | |
| Indent Indent Indent53034-5 | Allelic state | C | 0..1 | |
| Indent Indent Indent81258-6 | Sample variant allelic frequency [NFr] | O | 0..1 | % |
| Indent Indent Indent82121-5 | Allelic read depth | O | 0..1 | {#} |
| Indent Indent Indent82120-7 | Allelic phase | O | 0..1 | |
| Indent Indent Indent82309-6 | Basis for allelic phase [Type] | O |
Basic Attributes
- Class
- MOLPATH.MUT
- Type
- Laboratory
- First Released
- Version 2.58
- Last Updated
- Version 2.73 (MAJ)
- Change Reason
- Release 2.73: METHOD_TYP: Sequencing is too specific for this kind of testing where they use a combination of PCR and sequencing.;
- Order vs. Observation
- Both
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| el-GR | Greek (Greece) | Γονίδιο CALR εξώνιο 9 πλήρης ανάλυση μεταλλάξεων: Synonyms: Γονίδιο Γονίδιο CALR εξώνιο 9 Εύρεση |
| es-ES | Spanish (Spain) | gen CALR, exon 9 Análisis de mutación completa: |
| es-MX | Spanish (Mexico) | Análisis completo de mutación del exón 9 del gen CALR: |
| fr-FR | French (France) | CALR gène analyse complète des mutations de l'exon 9: |
| it-IT | Italian (Italy) | CALR, gene exon 9 Analisi di mutazione completa: Synonyms: Genetica molecolare Mutazione genica Osservazione Patologia molecolare Punto nel tempo (episodio) Sangue Sangue o Tessuto Tessuto & |
| nl-NL | Dutch (Netherlands) | CALR-gen exon 9 volledige mutatie-analyse: Synonyms: CALR gen exon 9 molgen |
| tr-TR | Turkish (Turkey) | CALR geni ekzon 9 tam mutasyon analizi: |
| zh-CN | Chinese (China) | CALR 基因外显子 9 全面突变分析: Synonyms: 临床文档型; |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=82538-0
LOINC Copyright
Copyright © 2025 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://